Last reviewed · How we verify
Rabeprazole sodium: Treatment B
Rabeprazole sodium: Treatment B is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. It is currently in Phase 1 development.
At a glance
| Generic name | Rabeprazole sodium: Treatment B |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib (PHASE1)
- A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults. (PHASE1)
- Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection (PHASE4)
- Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection (NA)
- A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. (PHASE1)
- Efficacies of HDDT With or Without Bismuth vs Amoxicillin-metronidazole BQT for First-line H Pylori Eradication (PHASE4)
- A Study of Maribavir Pediatric Formulation in Healthy Adult Participants (PHASE1)
- Standard or Short-course Vonoprazan Non-bismuth Triple Therapy or High-dose Dual Therapy Versus Rabeprazole-bismuth Quadruple Therapy for Primary Helicobacter Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rabeprazole sodium: Treatment B CI brief — competitive landscape report
- Rabeprazole sodium: Treatment B updates RSS · CI watch RSS
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. portfolio CI
Frequently asked questions about Rabeprazole sodium: Treatment B
What is Rabeprazole sodium: Treatment B?
Rabeprazole sodium: Treatment B is a Small molecule drug developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Who makes Rabeprazole sodium: Treatment B?
Rabeprazole sodium: Treatment B is developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (see full Johnson & Johnson Pharmaceutical Research & Development, L.L.C. pipeline at /company/johnson-johnson-pharmaceutical-research-development-l-l-c).
What development phase is Rabeprazole sodium: Treatment B in?
Rabeprazole sodium: Treatment B is in Phase 1.